Form 4 Filing for Dyne Therapeutics, Inc.

Dirk Kersten, a director at Dyne Therapeutics, Inc. (DYN), reported a series of stock sales on June 22 and June 23, 2026. These transactions were executed under a Rule 10b5-1 trading plan. On June 22, 2026, 190,676 shares of common stock were sold at a weighted average price of $20.5703, resulting in 3,921,542 shares remaining. On June 23, 2026, two separate transactions occurred: 71,629 shares were sold at a weighted average price of $21.0357, and an additional 1,657 shares were sold at a weighted average price of $21.4742. These sales reduced the total shares held to 3,848,256. The footnotes indicate that these shares are held indirectly through ForDyne, with ownership and dispositive power potentially attributed to various Forbion entities and partners, including Kersten Dirk himself, who is a partner and member of the investment committee.